Note: This summary is based on English-language coverage by MLex and other secondary sources, as the primary decision has not been published in English translation.
Background
The global battle over CRISPR-Cas9 gene-editing patents has been fought across multiple countries and patent offices for over a decade. In the United States, the Broad Institute of MIT and Harvard and the CVC group (University of California, University of Vienna, and Emmanuelle Charpentier) have waged a prolonged priority dispute over foundational CRISPR patents covering the use of CRISPR-Cas9 in eukaryotic (including human) cells. The Broad Institute has generally prevailed in the U.S., most recently in a March 2026 PTAB decision reaffirming its priority.
The fight has also played out in Japan. The Japan Patent Office (JPO) previously invalidated a key CRISPR patent held by the Broad Institute, MIT, and Harvard, concluding that the institutions could not legitimately claim priority from their earlier U.S. patent filings due to a dispute over the ownership of those priority rights. Priority rights are critical in patent law because they allow a later filing in one country to claim the benefit of an earlier filing date in another country — often the difference between a valid patent and an invalid one.
The Court’s Holding
On April 14, 2026, Japan’s Intellectual Property High Court overturned the JPO’s invalidation decision. The court ruled that the Broad Institute and its partner institutions could validly rely on their earlier U.S. filings to establish priority, despite challenges to the chain of ownership of those priority rights. The court found that the priority claim was legitimate and that the JPO had erred in invalidating the patent on those grounds.
This decision effectively revives the Broad Institute’s CRISPR patent protection in Japan, one of the world’s largest biotechnology markets. The ruling contrasts with the JPO’s earlier position and reinforces the Broad Institute’s global patent portfolio covering a technology that underpins an estimated $20+ billion industry spanning therapeutics, agriculture, and industrial biotechnology.
Key Takeaways
- The decision strengthens the Broad Institute’s CRISPR patent position in Japan, a critical market for gene-editing therapeutics and agricultural applications.
- The ruling addresses a fundamental question in international patent law: when can a patent applicant claim priority from foreign filings if the ownership of those priority rights is disputed? Japan’s IP High Court sided with allowing the claim.
- Companies commercializing CRISPR-based products in Japan will need to navigate the Broad Institute’s revived patent rights, potentially requiring licenses that the JPO invalidation would have avoided.
Why It Matters
CRISPR-Cas9 is arguably the most commercially important biotechnology invention of the 21st century, with applications ranging from cancer therapies to drought-resistant crops. The patent landscape is fragmented across jurisdictions — Broad has prevailed in the U.S. while CVC has secured key patents in Europe and previously in Japan. This decision tips the balance back toward Broad in Japan, a jurisdiction that matters enormously for the pharmaceutical and biotech industries.
For patent practitioners, the decision also provides important guidance on priority rights in international filings. The court’s willingness to uphold priority claims despite ownership disputes may encourage applicants to maintain aggressive international filing strategies even when domestic priority chains are under attack.